Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center.

L. F. Angel, T. H. Cai, E. Y. Sako, S. M. Levine

Research output: Contribution to journalArticle

16 Scopus citations


OBJECTIVES: Posttransplant lymphoproliferative disorders (PTLD) can be a significant cause of morbidity in lung transplant (LT) recipients. Risk factors include Epstein-Barr virus (EBV) infection, particularly primary infection, and immunosuppression. This article updates the incidence and presentation of PTLD at our lung transplant program. METHODS: We retrospectively reviewed the immunosuppression, EBV serology, and cases of PTLD among 129 lung transplant recipients at risk who survived > 1 month. RESULTS: There were two cases of PTLD among 129 LT patients, 2/129 (1.6%). One of these patients was among the 6 EBV seroconverters, 1/6 (16.7%), and had a typical presentation of PTLD in the allograft resulting in dissemination and death. The second case of PTLD developed in an EBV seropositive recipient who presented 33 months following LT with isolated colonic involvement. He subsequently died from chronic rejection. CONCLUSIONS: The incidence of PTLD in a LT program with a large EBV seropositive population is low, 1.6%. The presentation of PTLD in LT recipients is variable and may present typically with allograft involvement in the first year following transplantation, or late with isolated, extrapulmonic involvement.

Original languageEnglish (US)
Pages (from-to)26-30
Number of pages5
JournalAnnals of transplantation : quarterly of the Polish Transplantation Society
Issue number3
StatePublished - 2000


ASJC Scopus subject areas

  • Transplantation

Cite this